Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922620 | 0.85 | KMT2A (0.36) | SCN9AMAPTCFTRKDM4EMAPK10 | |
| SCHEMBL11922560 | 0.84 | ESRRA (0.37) | MAPTCFTRKDM4EALDH1A1POLB | |
| SCHEMBL11922595 | 0.82 | PTK2 (0.34) | SCN9APTK2LRRK2MAPTCFTR | |
| SCHEMBL11922609 | 0.81 | P2RY1 (0.46) | SCN9APTK2MAPTCFTR | |
| SCHEMBL13044739 | 0.76 | SCN9A (0.34) | SCN9APTK2 | |
| SCHEMBL11922613 | 0.75 | SCN9A (0.35) | SCN9ALRRK2MAPTKDM4EALDH1A1 | |
| SCHEMBL11991478 | 0.74 | PTK2 (0.32) | SCN9APTK2LRRK2CFTR | |
| SCHEMBL11922630 | 0.73 | SCN9A (0.33) | SCN9APTK2LRRK2KDM4EIRAK4 | |
| SCHEMBL13944249 | 0.73 | CFTR (0.33) | SCN9APTK2MAPTCFTRKDM4E | |
| SCHEMBL11991498 | 0.73 | PTK2 (0.33) | SCN9APTK2LRRK2CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242140-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| US-8242140-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | SCN9A 2265/4885PTK2 4598/4885LRRK2 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.